Clinically, the high TGFB1 (tumour) and TGFBR2 (CD4+ T cells) expression were jointly associated with inferior survival in HBV+ DLBCL, highlighting their potential as complementary prognostic markers capturing tumour‐immune interactions, distincted from established clinical predictors such as IPI, cell‐of‐origin, and double‐hit status.55, 56. This evidence concerns the gene CD4 and diffuse large B-cell lymphoma.